Combating Drug Resistant Gram-negative Infections: Giving Conventional Antibodies New Capabilities

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists, as well as other healthcare providers on the infectious disease care team and those interested in the management of patients with bacterial infections. No prerequisites required.


Program Overview

Gram-negative (GN) bacterial infections present a daunting challenge for clinicians, as they can be especially hard to treat and are associated with high morbidity and mortality, particularly when dealing with carbapenem-resistant Enterobacteriaceae (CRE) and other antibiotic-resistant pathogens. While the development of novel antibiotic classes to overcome resistance has been lacking, recent advances in the development of next-generation agents as of well-established classes has the potential to help address the critical need for effective therapies for serious, drug-resistant GN infections. As such, it is crucial for members of the infectious disease clinical team who treat these patients to understand how these emerging therapies differ from their more conventional predecessors, how they may effectively fit into current treatment paradigms, and how to effectively approach dosing and therapeutic drug management in order to optimize health outcomes for these difficult-to-treat patients.

Goal

The goal of this activity is to provide clinicians with learning and change strategies that result in measurable improvements in knowledge, competence, and/or performance relative to the care of patients with GN bacterial infections.

Learning Outcomes Statement

At the conclusion of this activity:

  1. KNOWLEDGE: Participants will self-report knowledge gained based on current best practices for improving outcomes and quality of life in patients with bacterial infections.
  2. COMPETENCE/SKILL: Participants will self-report intent to change practice by applying current best practices for improving outcomes and quality of life in patients with bacterial infections.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. RECOGNIZE the current challenges to treating serious Gram-negative (GN) infections including carbapenem-resistant infections, with currently available antibiotics.
  2. COMPARE the efficacy, safety, and activity against resistant GN pathogens of novel antibiotics versus conventional agents.
  3. DESCRIBE the principles of individualized dosing and therapeutic drug management for the use of novel antibiotics to treat GN infections in critically ill patients.

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Thomas M. File,Jr., MD, MSc, MACP, FIDSA, FCCP

Consultant/Advisor: Consultant/Advisor: bioMérieux Inc; Curetis USA Inc; GlaxoSmithKline plc; The Medicines Company; Merck & Co Inc; Motif Bio; Paratek; Pfizer Inc; and Shionogi Inc.

Emily L. Heil, PharmD, BCPS-AQ ID, AAHIVP

Grant/Research Support: ALK-Abelló.

Jason M. Pogue, PharmD, BCPS-ID

Consultant/Advisor: Achaogen Inc; The Medicines Company; Merck & Co Inc; Shionogi Inc; Zavante Therapeutics Inc.

Grant/Research Support: Merck & Co Inc.

Speakers’ Bureau: Allergan Inc; The Medicines Company; Merck & Co Inc.

Non-faculty

Sandy Breslow; Alison Kemp; Marilu Kelly, MSN, RN, CNE; Bernard M. Abrams, MD; Daniel Guinee; and Jessica Marshall, PhD; hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

Supported by an educational grant from Achaogen Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier and ASiM CE LLC.

CME CREDIT (PHYSICIANS)

The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE CREDIT (NURSES)

This continuing nursing education activity, provided by Elsevier, awards 1 contact hour for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681. Provider approved by the California Board of Registered Nursing, Provider #CEP 3257, for 1 contact hour.

CPE CREDIT (PHARMACISTS)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Elsevier Office of Continuing Medical Education will award 1.0 contact hours for this CPE activity.

ACPE Universal Activity #: 0631-9999-18-001-H01-P

Activity Type: Knowledge

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and ASiM CE LLC.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, ASiM CE LLC, and Achaogen, Inc do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. Nurses who attain a grade of 70% or higher on the post-activity test questions and who complete the evaluation before the expiration date will receive a certificate of completion for 1.0 contact hours. No partial credit will be awarded for this activity.
  7. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Release date: September 13, 2018
Expiration date: September 12, 2019